|Bid||0.00 x 900|
|Ask||192.99 x 1400|
|Day's Range||187.46 - 191.38|
|52 Week Range||134.53 - 197.86|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||52.12|
|Earnings Date||Jul 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||194.42|
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chairman & CEO of Edwards Lifesciences Corp (EW) Michael A Mussallem sold 22,850 shares of EW on 07/09/2019 at an average price of $189.14 a share.
EW has had some corrections and pullbacks along the way during this long and strong rally from $80 to nearly $200, but its price target is $240.
Edwards Lifesciences Corp NYSE:EWView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for EW with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.05 billion over the last one-month into ETFs that hold EW are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices. The agency said the company's voluntary recall of its IntraClude intra-aortic occlusion device in May has now been classified by the FDA as Class I. Class I recall is the strictest form of recall issued by the FDA, where use of faulty devices may cause serious injury or death.
Boston Scientific will likely top its own three-year guidance for a 6%-9% compound annual growth rate, analysts said Thursday as the medical technology company expands its heart devices.
While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Edwards Lifesciences Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
"We commend CMS on its thoughtful approach toward updating the TAVR policy. Throughout the NCD process, Edwards emphasized that the priority must be ensuring timely patient access to high-quality care, so that clinicians can provide all people with heart valve disease with the therapy that is right for them.
A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.
IRVINE, Calif. , June 4, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma ...
IRVINE, Calif., June 3, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received notice of an unsolicited "mini-tender offer" by TRC Capital Corporation to purchase up to 1,000,000 shares, or approximately 0.48 percent of the company's outstanding shares of common stock as of the date of the offer. Edwards does not endorse this unsolicited offer and recommends that the company's stockholders reject the offer, either by doing nothing in response or by withdrawing their shares from the offer, if they have responded. Edwards is not affiliated or associated in any way with TRC Capital, its mini-tender offer or the offer documentation.
Today we'll evaluate Edwards Lifesciences Corporation (NYSE:EW) to determine whether it could have potential as an...
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Today at the EuroPCR annual course in Paris, new 6-month data from the CLASP study of the PASCAL system were presented by Konstantinos Spargias, M.D., from the Hygeia Hospital in Athens, Greece. Patients enrolled in the CLASP study had clinically significant mitral regurgitation (MR) despite optimal medical therapy. The results from treatment with the PASCAL system demonstrated sustained positive outcomes at six months, including 81 percent of patients with mild (1+) or none/trace MR and 98 percent with 2+ MR, with echo core lab adjudication. Patients experienced clinically and statistically significant improvements in functional status, exercise capability and quality of life sustained at six months.
The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.
IRVINE, Calif., May 15, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Every Heartbeat Matters signature charitable initiative is on schedule to meet its goal of impacting the global burden of heart valve disease. The initiative, which involves the education, screening and treatment of 1.5 million underserved people by 2020, is supported by grants from Edwards Lifesciences Foundation, donations of Edwards heart valve technologies, volunteer support and the dedicated work of 60 non-profit partners. "Since the Every Heartbeat Matters initiative began five years ago, we have made substantial progress in building a global community that is addressing the burden of heart valve disease for underserved people," said Amanda Fowler, executive director, Edwards Lifesciences Foundation.